Cellular resistance mechanisms with impact on the therapy of multiple myeloma

Leukemia

Volumn 12, Issue 7, 1998, Pages 1009-1012

  Gieseler, F ^a   Nußler V ^b  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMSACRINE; CARRIER PROTEIN; CISPLATIN; CYTOKINE; DNA TOPOISOMERASE; DOXORUBICIN; ETOPOSIDE; GLUCOCORTICOID RECEPTOR; GLUTATHIONE TRANSFERASE; GLYCOPROTEIN P; GROWTH FACTOR; IMMUNOGLOBULIN FRAGMENT; MELPHALAN; PACLITAXEL; PARAPROTEIN; PROTEIN BCL 2; PROTEIN P53; STEROID RECEPTOR; VINCRISTINE;

APOPTOSIS; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CELL INFILTRATION; CELL MEMBRANE; CELL MEMBRANE TRANSPORT; CELL SURVIVAL; CONTROLLED STUDY; DETOXIFICATION; DRUG RESISTANCE; EDITORIAL; GENE MUTATION; HUMAN; HUMAN CELL; IMMUNOGLOBULIN PRODUCTION; MULTIPLE MYELOMA; MYELOMA CELL; ONCOGENE; ONCOGENE C MYC; ONCOGENE RAS; PLASMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; R FACTOR; RISK FACTOR; SUPPRESSOR GENE;

EID: 0031823174     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401060     Document Type: Editorial

References (13)

1. Takishita M, Kosaka M. Multiple myeloma: new evidence and insights from the immunoglobulin heavy chain gene and phenotypes. Leuk Lymphoma 1995; 19: 395-400.
2. Lai JL, Zandecki M, Mary JY, Bernardi F, Izydorczyk V, Flactif M, Morel P, Jouet JP, Bauters F, Facon T. Improved cytogenetics in multiple myeloma: a study of 151 patients including 117 paients at diagnosis. Blood 1995; 85: 2490-2497.
3. Niesvizky R, Siegel D, Michaeli J. Biology and treatment of multiple myeloma. Blood Rev 1993; 7: 24-33.
4. Lotem J, Sachs L. Regulation by bcl-2, c-myc, and p53 of susceptibility to induction of apoptosis by heat shock and cancer chemotherapy compounds in differentiation-competent and -defective myeloid leukemic cells. Cell Growth Differ 1993; 4: 41-47.
5. Kamesaki S, Kamesaki H, Jorgensen TJ, Tanizawa A, Pommier Y, Cossman J. bcl-2 protein inhibits etoposide-induced apoptosis through its effects on events subsequent to topoisomerese II-induced DNA strand breaks and their repair. Cancer Res 1993; 53: 4251-4256.
6. Petrini M, Di Simone D, Favati A, Mattii L, Valentini P, Grassi B. GST-pi and P-170 co-expression in multiple myeoma. Br J Haematol 1995; 90: 393-397.
7. Pileri A, Ferrero D, Massaia M, Dianzani U,Boccadoro M. Advances in biology of multiple myeloma: cell kinetics, molecular biology and immunology. Eur J Haematol Suppl 1989; 51: 30-34.
8. Nooter K, Boersma AW, Oostrum RG, Burger H, Jochemsen AG, Stoter G. Constitutive expression of the c-H-ras oncogene inhibits doxorubicin-induced apoptosis and promotes cell survival in a rhabdomyosarcoma cell line. Br J Cancer 1995; 71: 556-561.
9. Riva C, el Khyari S, Rustum Y, Barra Y. Resistance to cytosine arabinoside in cells transfected with activated Ha-ras oncogene. Anticancer Res 1995; 15: 1297-1302.
10. Bataille R, Klein B. Mechanisms of bone lesions in multiple myeloma. Hematol/Oncol Clin North Am 1992; 6: 285-295.
11. Zhang XG, Klein B, Bataille R. Interleukin-6 is a potent myeloma-cell growth factor in patients with aggressive multiple myeloma. Blood 1989; 74: 11-13.
12. Kyle RA. Prognostic factors in multiple myeloma. Stem Cells 1995; 13 (Suppl. 2): 56-63.
13. Reibnegger G, Krainer M, Herold M, Ludwig H, Wachter H, Huber H. Predictive value of interleukin-6 and neopterin in patients with multiple myeloma. Cancer Res 1991; 51: 6250-6253.